Archives: Agenda

• How Eikon is deploying AI today across vendor oversight, demand planning, compliance documentation and stakeholder communication
• Separating Real-World Value from the Hype: Discover what worked, what failed, and what the team would do differently, gaining a grounded perspective on where AI delivers genuine ROI versus where it falls short
• Learn how practical AI tools are uncovering hidden logistics risks and driving operational efficiencies in ways traditional supply chain software simply cannot match

• How AI tools support today’s journey – and enable tomorrow’s connected experience
• AI is reshaping the car-buying journey — adding context, clarity and confidence.
• Using concrete examples from de, we will share learnings from implementing AI for consumers and dealers.
• We will explore how AI complements classic tools and creates value for both sides of the marketplace

• Automation from scan to end-point
• Imaging biomarkers and experts
• Site connectivity for full traceability

• Addressing logistical challenges in clinical trials for blood sample processing.
• Implementing solutions to stabilize biomarkers at collection and simplify workflows.

In this session will explore how the next generation of AI can move clinical development beyond search, dashboards, and isolated use cases toward intelligent workflows that help teams synthesize complex information, surface relevant insights, and act with greater speed and confidence.

Key Discussion Points:

• Move beyond AI experimentation to practical clinical impact, exploring where AI can meaningfully improve decisions across study design, feasibility, and site selection.
• Learn why AI is only as effective as the data and clinical context behind it and why fragmented inputs can limit even the most sophisticated models.
• Explore the shift from searching for information to working with intelligent clinical workflows that can synthesize complex data, surface insights, and help teams determine what to do next.
• Understand where AI should augment, not replace, human expertise, particularly for complex decisions involving investigators, sites, countries, and trial strategy.
• See what the next generation of clinical intelligence could look like when connected data, AI, and workflows come together to support faster, more confident decision-making.

• Evaluating CRO capabilities and experience relevant to your specific therapeutic area and development stage
• Balancing cost, quality and timelines within tight budget constraints
• Negotiating contracts with flexibility to protect your biotech’s goals

This session will explore whether the FDA’s Real-Time Clinical Trials (RTCT) program is an aspirational vision for the future or a near-term reality that biotech companies should begin preparing for today. This session will discuss what sponsors can do now to position themselves for participation in this emerging real-time development model.

• Separate hype from reality: Examine FDA’s stated goals for RTCTs, the scope of the pilot program, and its potential opportunities and limitations.
• Understand the broad operational and technology requirements: Identify the critical capabilities needed for participation in the pilot program.
• Develop your biotech readiness roadmap: Discuss practical actions sponsors can take today to assess their organizational readiness and engage with FDA as the RTCT model evolves.

• What “real time” looked like from the sponsor side when site activity became visible only after the work was complete
• How late queries and accessioning delays slowed data readout in a Phase I oncology study
• What changed when issues were identified and corrected before shipment
• Why clinical trial execution is foundational to better data and AI-ready trials